First‐to‐Patent Does not Predict First‐ or Best‐in‐Class: Analysis of Approved Small Molecule vs. Biologic Drugs

Publisher: John Wiley & Sons Inc

E-ISSN: 1532-6535|97|1|19-21

ISSN: 0009-9236

Source: CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.97, Iss.1, 2015-01, pp. : 19-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract